Skip to main content

Table 1 Patient characteristics

From: Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study

Characteristics All patients FP group F group p-value
(n = 129) (n = 64) (n = 65)
No. (%) No. (%) No. (%)
Age (years)
 Median (range) 65 (24–94) 62 (27–94) 67 (24–89) 0.02
 < 65 61 (47) 36 (56) 25 (38) 0.04
> 65 68 (53) 28 (44) 40 (62)  
Sex
 Male 68 (53) 33 (52) 35 (54) 0.80
 Female 61 (47) 31 (48) 30 (46)  
ECOG PS
 0 9 (7) 4 (6) 5 (8)  
 1 68 (53) 41 (64) 27 (42)  
 2 44 (34) 16 (25) 28 (43)  
 3 7 (5) 2 (3) 5 (8)  
 4 1 (1) 1 (2) 0 (0)  
 0–1 77 (60) 45 (70) 32 (49) 0.01
 2–4 52 (40) 19 (30) 33 (51)  
Histology
 Intestinal 22 (17) 10 (16) 12 (18) 0.81
 Diffuse 102 (79) 52 (81) 50 (77)  
 Unknown 5 (4) 2 (3) 3 (5)  
Disease status
 Advanced 120 (93) 58 (91) 62 (95) 0.29
 Recurrent 9 (7) 6 (9) 3 (5)  
Primary tumor
 Presence 113 (88) 54 (84) 59 (91) 0.27
 Absence 16 (12) 10 (16) 6 (9)  
Primary site
 Stomach 123 (95) 59 (92) 64 (98) 0.09
 GEJ 6 (5) 5 (8) 1 (2)  
No. of metastatic sites
 1–2 100 (78) 49 (77) 51 (78) 0.80
> 3 29 (22) 15 (23) 14 (22)  
Target lesion
 Presence 56 (43) 24 (38) 32 (49) 0.18
 Absence 73 (57) 40 (62) 33 (51)  
Subtype of SPM
 Massive ascites 62 (48) 39 (61) 23 (35) 0.01
 Inadequate oral intake 35 (27) 16 (25) 19 (29)  
 Both 32 (25) 9 (14) 23 (35)  
Serum albumin level (g/ml)
 Median (range) 3.1 (1.8–4.4) 3.1 (1.8–4.3) 3.1 (1.8–4.4) 0.87
Serum CRP level (mg/dl)
 Median (range) 2.2 (0.0–24.0) 1.8 (0.1–20.7) 2.6 (0.0–24.0) 0.86
  1. CRP C-reactive protein, ECOG PS: Eastern Cooperative Oncology Group performance status, GEJ gastroesophageal junction, SPM severe peritoneal metastasis